Our Expanding View of Platelet Functions and Its Clinical Implications

被引:33
作者
Ombrello, Christopher [2 ]
Block, Robert C. [2 ]
Morrell, Craig N. [1 ]
机构
[1] Univ Rochester, Sch Med, Dept Med, Aab Cardiovasc Res Inst, Rochester, NY 14642 USA
[2] Univ Rochester, Sch Med, Dept Community & Prevent Med, Rochester, NY 14642 USA
基金
美国国家卫生研究院;
关键词
Platelet; Inflammation; Thrombosis; Aggregation; Activation; Therapy; PERCUTANEOUS CORONARY INTERVENTION; VON-WILLEBRAND-FACTOR; TIMI; 38; TRIAL; ANTIPLATELET THERAPY; VASCULAR BIOLOGY; STENT THROMBOSIS; IN-VIVO; ANUCLEATE PLATELETS; PARKINSONS-DISEASE; RESISTANT PATIENTS;
D O I
10.1007/s12265-010-9213-7
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Platelets are the primary cell mediator of thrombosis. A deficiency of platelets can result in severe bleeding defects. "Overactive" platelets contribute to life-threatening outcomes in diseases such as heart attack, stroke, and cancer. The use of platelet inhibitors for thrombosis prevention must therefore seek a delicate balance between inhibiting platelet activation and an associated increased bleeding risk. There are currently few platelet inhibitors clinically available, making the search for novel antiplatelet drug targets a major research priority. Several newly identified pathways of platelet activation may hold hope in this area. In addition, important roles for platelets beyond hemostasis have been discovered. Platelets have recently been described as mediators of diverse inflammatory diseases such as arthritis, hepatitis, malaria, and atherosclerosis. This has heightened the need to broaden our understanding of platelet functions and platelet-derived inflammatory mediators. It has also heightened interest in a continued search for new platelet inhibitors and presents new opportunities for platelet inhibitors to be used in a wide array of disease treatment strategies.
引用
收藏
页码:538 / 546
页数:9
相关论文
共 72 条
[1]   Platelet physiology and thrombosis [J].
Andrews, RK ;
Berndt, MC .
THROMBOSIS RESEARCH, 2004, 114 (5-6) :447-453
[2]   Antidote-Controlled Antithrombotic Therapy Targeting Factor IXa and Von Willebrand Factor [J].
Becker, Richard C. ;
Oney, Sabah ;
Becker, Kristian C. D. ;
Sullenger, Bruce .
OLIGONUCLEOTIDE THERAPEUTICS, 2009, 1175 :61-70
[3]   Safety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel, a direct-acting and reversible P2Y12 ADP-receptor antagonist, before primary percutaneous intervention in patients with ST-elevation myocardial infarction: The Early Rapid ReversAl of Platelet ThromboSis with Intravenous Elinogrel before PCI to Optimize REperfusion in Acute Myocardial Infarction (ERASE MI) pilot trial [J].
Berger, Jeffrey S. ;
Roe, Matthew T. ;
Gibson, C. Michael ;
Kilaru, Rakhi ;
Green, Cynthia L. ;
Melton, Laura ;
Blankenship, James D. ;
Metzger, D. Christopher ;
Granger, Christopher B. ;
Gretler, Daniel D. ;
Grines, Cindy L. ;
Huber, Kurt ;
Zeymer, Uwe ;
Buszman, Pawel ;
Harrington, Robert A. ;
Armstrong, Paul W. .
AMERICAN HEART JOURNAL, 2009, 158 (06) :998-U145
[4]   Platelet glutamate receptor supersensitivity in major depressive disorder [J].
Berk, M ;
Plein, H ;
Ferreira, D .
CLINICAL NEUROPHARMACOLOGY, 2001, 24 (03) :129-132
[5]   Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting - The Clopidogrel Aspirin Stent International Cooperative Study (CLASSICS) [J].
Bertrand, ME ;
Rupprecht, HJ ;
Urban, P ;
Gershlick, AH .
CIRCULATION, 2000, 102 (06) :624-629
[6]   Platelets Amplify Inflammation in Arthritis via Collagen-Dependent Microparticle Production [J].
Boilard, Eric ;
Nigrovic, Peter A. ;
Larabee, Katherine ;
Watts, Gerald F. M. ;
Coblyn, Jonathan S. ;
Weinblatt, Michael E. ;
Massarotti, Elena M. ;
Remold-O'Donnell, Eileen ;
Farndale, Richard W. ;
Ware, Jerry ;
Lee, David M. .
SCIENCE, 2010, 327 (5965) :580-583
[7]   Tailored Clopidogrel Loading Dose According to Platelet Reactivity Monitoring to Prevent Acute and Subacute Stent Thrombosis [J].
Bonello, Laurent ;
Camoin-Jau, Laurence ;
Armero, Sebastien ;
Com, Olivier ;
Arques, Stephane ;
Burignat-Bonello, Caroline ;
Giacomoni, Marie-Paule ;
Bonello, Roland ;
Collet, Frederic ;
Rossi, Philippe ;
Barragan, Paul ;
Dignat-George, Francoise ;
Paganelli, Franck .
AMERICAN JOURNAL OF CARDIOLOGY, 2009, 103 (01) :5-10
[8]   Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel [J].
Brandt, J. T. ;
Close, S. L. ;
Iturria, S. J. ;
Payne, C. D. ;
Farid, N. A. ;
Ernest, C. S., II ;
Lachno, D. R. ;
Salazar, D. ;
Winters, K. J. .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2007, 5 (12) :2429-2436
[9]   Minding the gaps to promote thrombus growth and stability [J].
Brass, LF ;
Zhu, L ;
Stalker, TJ .
JOURNAL OF CLINICAL INVESTIGATION, 2005, 115 (12) :3385-3392
[10]   Coagulation and platelet activation pathways - A review of the key components and the way in which these can be manipulated [J].
Buller, HR ;
TenCate, JW .
EUROPEAN HEART JOURNAL, 1995, 16 :8-10